Previous 10 | Next 10 |
The USPTO has issued a patent to Humanigen (HGEN) for the use of lenzilumab in prevention or treatment of cytokine storm, neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy and inhibit or reduce incidence or severity of CAR-T-related toxicities. Th...
Humanigen, Inc . (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced the Uni...
Gainers: Mereo BioPharma (MREO) +91%, Cyclo Therapeutics (CYTH) +44%, Petros Pharmaceuticals (PTPI) +29%, CNS Pharmaceuticals (CNSP) +17%, Humanigen (HGEN) +17%.Losers: Mesoblast (MESO) -34%, Virios Therapeutics (VIRI) -30%, BioCardia (BCDA) -...
Humanigen (HGEN) has completed enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme ((GBM)).Results from the study, being conducted in Australia, are expected in H1 2021. The primary goal of the Phase 1 study is to evaluate sa...
Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...
Humanigen, Inc . (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 ...
vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...
New Humanigen entity in Australia creates focused opportunity for partnering, regional clinical trials and market access Structure allows for attractive financial incentives supported by the Australian government Humanigen, Inc . (NASDAQ: HGEN) (&...
Humanigen (HGEN): Q3 GAAP EPS of -$0.71 misses by $0.16.As of September 30, 2020, the Company had cash and cash equivalents of $91.4M. We expect our expenses to continue to increase significantly in the remaining three months of 2020 as a result of securing additional manufacturing capac...
-Underwritten Public Offering and Nasdaq Listing Completed in September 2020 -Positive Phase 3 Interim Analysis Reported with an Estimated 37 percent More Recoveries Observed in the Lenzilumab Arm Versus Current Standard of Care Humanigen, Inc. , (HGEN)...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...